利拉鲁肽对2型糖尿病合并代谢综合征患者的疗效研究

Efficacy study of Liraglutide in patients with type 2 diabetic patients combined with metabolic syndrome

目的:观察利拉鲁肽对2型糖尿病合并代谢综合征患者的临床疗效。方法:选取2型糖尿病合并代谢综合征患者128例为研究对象,给予患者利拉鲁肽治疗,并随访30周。治疗前后,观察患者的体重、体重指数(BMI)、腰围、血压、空腹胰岛素(FINS)、空腹C肽(FCP)、空腹血糖(FPG)、餐后2 h血糖(2 hPG)、糖化血红蛋白(HbA1C)、总胆固醇(TC)、甘油三酯(TG)和低密度脂蛋白胆固醇(LDL-C)等化验指标,并计算胰岛β细胞功能指数(HOMA-β)和胰岛素抵抗指数(HOMA-IR)。结果:接受利拉鲁肽治疗后,患者的体重、BMI、腰围值较治疗前下降,差异有统计学意义(P<0.05);与治疗前相比,患者的FBG、2 hPG、HBA1C明显降低,有显著性差异(P<0.01),TG水平下降,差异有统计学意义(P<0.05);血压及TC、LDL-C变化无统计学意义(P>0.05);FINS、FCP、HOMA-β明显提升,HOMA-IR明显降低,差异有统计学意义(P<0.05)。结论:给予2型糖尿病合并代谢综合征患者利拉鲁肽治疗,可显著降低其血糖水平、减少体重、降低血脂,并且改善其胰岛β细胞分泌功能。

Objective： To observe clinical efficacy of Liraglutide in type 2 diabetic patients with metabolic syndrome. Methods： 128 patients with type 2 diabetes and metabolic syndrome were selected as the subjects,given the Liraglutide treatment,and were followed-up for 30 weeks. Before and after the treatment,the body weight,body mass index（ BMI）,waist circumference,blood pressure,fasting insulin（ FINS）,fasting C peptide（ FCP）,fasting blood glucose（ FBG）,2h postprandial blood glucose（ 2hPG）,glycosylated hemoglobin（ HbA1C）,total cholesterol（ TC）,triglyceride（ TG）,low density lipoprotein cholesterol（ LDL-C）,and other laboratory indicators were observed,and the Islet β cell function index in HOMA（ HOMA-β） and insulin resistance index in HOMA（ HOMA-IR） were calculated. Results： The differencesof the body weight,BMI,and waist circumference before and after the Liraglutide treatment were statistically significant（ P 〈0. 05）. Compared with those before the treatment,the levels of FBG,2h PG,and HBA1 C after the treatment decreased significantly（ P〈0.01）,and TG level decreased（ P〈0.05）. There were no statistical differences in the blood pressure and the levels of TC and LDL-C before and after the treatment（ P〉0.05）. Further,after the treatment,the levels of FINS,FCP and HOMA-β significantly increased,but HOMA-IR obviously decreased（ P〈 0. 05）. Conclusions： Liraglutide can play the role of decreasingblood glucose,losing weight,lowering blood lipid and improving islet β cell secretory function in the patients with Type 2 diabetic and metabolic syndrome.